Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type
- 26 January 2016
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 86 (4), 360-366
- https://doi.org/10.1212/wnl.0000000000002310
Abstract
Objective: To compare intracerebral hemorrhage (ICH) volume and clinical outcome of non–vitamin K oral anticoagulants (NOAC)–associated ICH to warfarin-associated ICH. Methods: In this multicenter cross-sectional observational study of patients with anticoagulant-associated ICH, consecutive patients with NOAC-ICH were compared to those with warfarin-ICH selected from a population of 344 patients with anticoagulant-associated ICH. ICH volume was measured by an observer blinded to clinical details. Outcome measures were ICH volume and clinical outcome adjusted for confounding factors. Results: We compared 11 patients with NOAC-ICH to 52 patients with warfarin-ICH. The median ICH volume was 2.4 mL (interquartile range [IQR] 0.3–5.4 mL) for NOAC-ICH vs 8.9 mL (IQR 4.0–21.3 mL) for warfarin-ICH (p = 0.0028). In univariate linear regression, use of warfarin (difference in cube root volume 1.61; 95% confidence interval [CI] 0.69 to 2.53) and lobar ICH location (compared with nonlobar ICH; difference in cube root volume 1.52; 95% CI 2.20 to 0.85) were associated with larger ICH volumes. In multivariable linear regression adjusting for confounding factors (sex, hypertension, previous ischemic stroke, white matter disease burden, and premorbid modified Rankin Scale score [mRS]), warfarin use remained independently associated with larger ICH (cube root) volumes (coefficient 0.64; 95% CI 0.24 to 1.25; p = 0.042). Ordered logistic regression showed an increased odds of a worse clinical outcome (as measured by discharge mRS) in warfarin-ICH compared with NOAC-ICH: odds ratio 4.46 (95% CI 1.10 to 18.14; p = 0.037). Conclusions: In this small prospective observational study, patients with NOAC-associated ICH had smaller ICH volumes and better clinical outcomes compared with warfarin-associated ICH.Keywords
This publication has 26 references indexed in Scilit:
- Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With RivaroxabanStroke, 2013
- Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or DabigatranStroke, 2012
- The Oral Thrombin Inhibitor Dabigatran: Strengths and WeaknessesSeminars in Thrombosis and Hemostasis, 2012
- Cerebral Microbleeds on Magnetic Resonance Imaging and Anticoagulant-Associated Intracerebral Hemorrhage RiskFrontiers in Neurology, 2012
- Rivaroxaban: A New Oral Factor Xa InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based studyThe Lancet Neurology, 2007
- Investigational treatments of venous thromboembolismExpert Opinion on Investigational Drugs, 2007
- A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CTStroke, 2001
- Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibodyThrombosis Research, 1990
- A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage.Journal of Neurology, Neurosurgery & Psychiatry, 1990